RBC Capital analyst Luca Issi maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report) on August 3 and set a price target of $90.00. The company's shares closed last Friday at $95.82. According to TipRanks.com, Issi 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -11.2% and a 38.9% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Crispr Therapeutics AG. The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioMarin Pharmaceutical with a $109.79 average price target, representing a 19.5% upside.
https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-hold-rating-on-biomarin-pharmaceutical-bmrn?utm_source=advfn.com&utm_medium=referral
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more BioMarin Pharmaceutical Charts.
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more BioMarin Pharmaceutical Charts.